People: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

9.55EUR
4 Mar 2015
Change (% chg)

€-0.00 (-0.01%)
Prev Close
€9.55
Open
€9.79
Day's High
€9.79
Day's Low
€9.50
Volume
191,166
Avg. Vol
161,176
52-wk High
€11.48
52-wk Low
€7.40

Search Stocks

Fellner, Peter 

Brief Biography

Dr. Peter J. Fellner, Ph.D., has served as Chairman of the Board of Directors of Ablynx NV since 2013. He is currently Chairman of the Board of Consort Medical and Optos. In addition, he serves as Chairman of the biotech companies Vernalis and Biotie Therapies, and is Vice Chairman of Astex Pharmaceuticals, which is being acquired by Otsuka Pharmaceuticals. He is currently a Director of the global biopharmaceutical company UCB, where he is Chairman of the Science Committee of the Board, and is a Member of the Novo A/S Advisory Group. He previously served as Chairman of Acambis from 2006 until its acquisition by Sanofi Aventis in 2008, and of Premier Research Group from 2007 to 2008, when it was acquired by a private-equity backed group. He also served as Chairman of Celltech Group from 2003 to July 2004, until its acquisition by UCB, having been Chief Executive Officer from 1990 onwards. Before joining Celltech, he was Chief Executive Officer of Roche UK from 1986 to 1990.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Search Stocks